What you should know:
1. Bone Biologics concluded a preclinical study of rhNELL-1. Researchers found the product was well tolerated with no inflammation.
2. Bone Biologics intends to build on the preclinical results and launch a clinical trial at a later date.
3. Researchers tested the rhNELL-1 product on sheep, finding increases in fusion and quantity of bone when compared to a control.
4. Bone Biologics received approval to test rhNELL-1 on 30 patients in Australia in a multicenter pilot clinical trial.
More articles on biologics:
Dr. Bryan Little appointed to state medical board, task force
Former Medtronic, Bioventus executive becomes CEO at BlueWind Medical
Exactech co-founders retire, current CEO to transition to board role — 4 insights
